- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations
This study is testing a new medicine, JNJ-42756493, for adults and children with advanced cancers that have a specific genetic change called an FGFR alteration. Researchers want to see if the medicine can shrink or make these cancers disappear.
For: Advanced solid tumors (other than Urothelial tumors) · and FGFR gene alterations.Germany · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
This study looks at a new drug, erdafitinib, for people with advanced bladder cancer that has a specific gene change. It compares erdafitinib to standard treatments like pembrolizumab, docetaxel, or vinflunine to see if it helps people live longer.
For: Advanced Urothelial CancerFrance · Spain · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
This study is for people with a type of non-muscle-invasive bladder cancer that has come back after treatment. We're testing a new drug, erdafitinib, against standard treatments to see which is better at preventing the cancer from returning.
For: Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or FusionsFrance · Germany · Poland